scholarly journals Radiological Assessment and Outcome of Local Disease Progression after Neoadjuvant Chemotherapy in Children and Adolescents with Localized Osteosarcoma

2020 ◽  
Vol 9 (12) ◽  
pp. 4070
Author(s):  
Adriana Fonseca ◽  
Anne L. Ryan ◽  
Paul Gibson ◽  
Eleanor Hendershot ◽  
Sevan Hopyan ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Interobserver Reliability ◽  
Evaluation Criteria ◽  
Progression Free Survival ◽  
Kappa Statistic ◽  
Response Assessment ◽  
Rank Test ◽  
Response Evaluation ◽  
Radiological Criteria ◽  
Response Evaluation Criteria

Objective: We examined the interobserver reliability of local progressive disease (L-PD) determination using two major radiological response evaluation criteria systems (Response evaluation Criteria in Solid Tumors (RECIST) and the European and American Osteosarcoma Study (EURAMOS)) in patients diagnosed with localized osteosarcoma (OS). Additionally, we describe the outcomes of patients determined to experience L-PD. Materials and Methods: Forty-seven patients diagnosed with localized OS between 2000 and 2012 at our institution were identified. Paired magnetic resonance imaging of the primary tumor from diagnosis and post-neoadjuvant chemotherapy were blindly assessed by two experienced radiologists and determined L-PD as per RECIST and EURAMOS radiological criteria. Interobserver reliability was measured using the kappa statistic (κ). The Kaplan Meier method and log-rank test was used to assess differences between groups. Results: Of 47 patients (median age at diagnosis 12.9 years), 16 (34%) had L-PD (by RECIST or EURAMOS radiological definition). There was less agreement between the radiologists using EURAMOS radiological criteria for L-PD (80.9%, κ = 0.48) than with RECIST criteria (97.9%, κ = 0.87). Patients with radiologically defined L-PD had a 5-year progression-free survival (PFS) of 55.6%, compared to a 5 year-PFS of 82.7% in the group of patients without L-PD (n = 31) (Log rank p = 0.0185). Conclusions: The interobserver reliability of L-PD determination is higher using RECIST than EURAMOS. RECIST can be considered for response assessment in OS clinical trials. The presence of L-PD was associated with worse outcomes.

Case 1 – Maintenance treatment with trabectedin in advanced soft tissue sarcomas: when should we consider progression?

2016 ◽  
Vol 4 (2) ◽  
pp. 42-47
Author(s):  
Diego Soto De Prado y Otero ◽  
Jesús Angel Palencia Ercilla ◽  
Alejandro León Andrino ◽  
Mercedes Alonso Rodríguez ◽  
Gerardo Martínez García ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Maintenance Treatment ◽  
Locally Advanced ◽  
Evaluation Criteria ◽  
Soft Tissue Sarcomas ◽  
Response Evaluation ◽  
Clinical Progression ◽  
Radiological Progression ◽  
Metastatic Relapse ◽  
Response Evaluation Criteria

We present the case of a patient with a locally advanced synovial sarcoma treated with neoadjuvant chemotherapy and subsequent surgery who presented an early metastatic relapse, wherein a rapid and significant response was achieved with trabectedin, and in whom maintenance of the drug until clinical progression of the disease allowed 27 cycles of treatment to be administered despite the patient presenting radiological progression according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria 15 cycles earlier.

Response Assessment in Pediatric Rhabdomyosarcoma: Can Response Evaluation Criteria in Solid Tumors Replace Three-dimensional Volume Assessments?

Radiology ◽  
2013 ◽  
Vol 269 (3) ◽  
pp. 870-878 ◽  
Author(s):  
Reineke A. Schoot ◽  
Kieran McHugh ◽  
Rick R. van Rijn ◽  
Leontien C. M. Kremer ◽  
Julia C. Chisholm ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Three Dimensional ◽  
Evaluation Criteria ◽  
Response Assessment ◽  
Response Evaluation ◽  
Response Evaluation Criteria

Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma

2017 ◽  
Vol 65 (4) ◽  
pp. e26896 ◽  
Author(s):  
Lillian M. Guenther ◽  
R. Grant Rowe ◽  
Patricia T. Acharya ◽  
David W. Swenson ◽  
Stephanie C. Meyer ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Solid Tumors ◽  
Evaluation Criteria ◽  
Response Evaluation ◽  
Response Evaluation Criteria

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

2018 ◽  
Vol 36 (9) ◽  
pp. 850-858 ◽  
Author(s):  
F. Stephen Hodi ◽  
Marcus Ballinger ◽  
Benjamin Lyons ◽  
Jean-Charles Soria ◽  
Mizuki Nishino ◽  
...  
Keyword(s):  
Disease Control ◽  
Cancer Immunotherapy ◽  
Solid Tumors ◽  
Evaluation Criteria ◽  
Progression Free Survival ◽  
Target Lesion ◽  
Response Evaluation ◽  
Overall Response ◽  
Metastatic Urothelial Carcinoma ◽  
Response Evaluation Criteria

Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to better capture CIT responses. Patients and Methods Atezolizumab data from clinical trials in non–small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. Modifications to imRECIST versus RECIST v1.1 included allowance for best overall response after progressive disease (PD) and changes in PD definitions per new lesions (NLs) and nontarget lesions. imRECIST progression-free survival (PFS) did not count initial PD as an event if the subsequent scan showed disease control. OS was evaluated using conditional landmarks in patients whose PFS differed by imRECIST versus RECIST v1.1. Results The best overall response was 1% to 2% greater, the disease control rate was 8% to 13% greater, and the median PFS was 0.5 to 1.5 months longer per imRECIST versus RECIST v1.1. Extension of imRECIST PFS versus RECIST v1.1 PFS was associated with longer or similar OS. Patterns of progression analysis revealed that patients who developed NLs without target lesion (TL) progression had a similar or shorter OS compared with patients with RECIST v1.1 TL progression. Patients infrequently experienced a spike pattern (TLs increase, then decrease) but had longer OS than patients without TL reversion. Conclusion Evaluation of PFS and patterns of response and progression revealed that allowance for TL reversion from PD per imRECIST may better identify patients with OS benefit. Progression defined by the isolated appearance of NLs, however, is not associated with longer OS. These results may inform additional modifications to radiographic criteria (including imRECIST) to better reflect efficacy with CIT agents.

Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond

2018 ◽  
pp. 1019-1029 ◽  
Author(s):  
Mizuki Nishino
Keyword(s):  
Cancer Therapy ◽  
Solid Tumors ◽  
Tumor Response ◽  
Objective Assessment ◽  
Evaluation Criteria ◽  
Therapy Response ◽  
Response Assessment ◽  
Cancer Therapies ◽  
Response Evaluation ◽  
Response Evaluation Criteria

Objective assessment of tumor responses and treatment results has been the basis for the advancement of cancer therapies, and imaging plays a key role to provide a “common language” to describe the results of cancer treatment. Although Response Evaluation Criteria in Solid Tumors (RECIST) has been the most widely accepted method for assessing tumor response in the past decades, the limitations of RECIST have increasingly becoming recognized, especially with the recent advances of precision-medicine approaches to cancer. This article reviews the current concept of tumor response evaluations based on RECIST, describes the limitations of RECIST, and proposes strategies to overcome the limitations. The article emphasizes specific limitations in the setting of precision cancer therapy and cancer immunotherapy and discusses the important insights provided by the cutting-edge investigations in the emerging fields.

scholarly journals Evaluating the effect of Neoadjuvant chemotherapy for esophageal Cancer using the RECIST system with shorter-axis measurements: a retrospective multicenter study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yusuke Taniyama ◽  
Kentaro Murakami ◽  
Naoya Yoshida ◽  
Kozue Takahashi ◽  
Hisahiro Matsubara ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Solid Tumors ◽  
Multicenter Study ◽  
Treatment Effects ◽  
Evaluation Criteria ◽  
Pathological Response ◽  
Tumor Diameter ◽  
Response Evaluation ◽  
Response Evaluation Criteria

Abstract Background Evaluating the effect on primary lesions is important in determining treatment strategies for esophageal cancer. The Response Evaluation Criteria in Solid Tumors system, which employs the longest diameter for measuring tumors, is commonly used for evaluating treatment effects. However, the usefulness of these criteria in assessing primary esophageal tumors remains controversial. Thus, we evaluated this issue by measuring not only the longest diameter but also the shorter axis of the tumor. Methods We retrospectively reviewed data from 313 patients with esophageal cancer treated with neoadjuvant chemotherapy followed by esophagectomy at three major high-volume centers in Japan. All patients underwent contrast-enhanced computed tomography before and after chemotherapy. The longest and shortest tumor diameters were measured in each case. Treatment effects were adapted to the Response Evaluation Criteria in Solid Tumors system. Correlations between pathological and survival data were also analyzed. Results Inter-observer discrepancies were examined for changes in the longest diameter and shorter axis of the tumor (the intraclass correlation coefficients were 0.550 and 0.624, respectively). The shorter axis was correlated with the pathological response in the multivariate analysis (p < 0.001). The shorter axis was significantly associated with overall survival and disease-free survival (both p < 0.001), whereas this association was not observed for the longest tumor diameter. Conclusions This multicenter study demonstrated that the Response Evaluation Criteria in Solid Tumors system is useful for predicting pathological response and survival by incorporating the shorter axis of the primary esophageal tumor.

Sign in / Sign up

Export Citation Format

Share Document